Theralink Technologies, Inc. (Theralink or the Company) announced that it has appointed Dr. Mattia Cremona as its Director of its Biopharma Laboratory effective November 7, 2022. Dr. Cremona is a molecular biologist, with a specialty in translation oncology research. During his career, he has worked in several research hospitals in Europe and the US, most recently as a Research Fellow at the Royal College of Surgeons in Ireland (RCSI), where he established the first Reverse Phase Protein Array (RPPA) Platform.

Dr. Cremona's research involves using proteomic high-throughput approaches to study the status of the proteins inside cancer cells and to highlight changes with normal cells that could explain why patients do not respond to therapy or develop resistance after an initial response. He has contributed articles to several leading peer-reviewed journals, including Cancer and The British Journal of Cancer. He has presented at many international conferences and his published research has been frequently cited.

Dr. Cremona completed his PhD in Molecular Medicine at Universita' degli Studi di Milano in 2009.